Activities of Moxifloxacin against, and Emergence of Resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an In Vitro Pharmacokinetic Model
Open Access
- 1 March 2003
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (3) , 1088-1095
- https://doi.org/10.1128/aac.47.3.1088-1095.2003
Abstract
The pharmacodynamics of moxifloxacin against Streptococcus pneumoniae and Pseudomonas aeruginosa were investigated in a pharmacokinetic infection model. Three strains of S. pneumoniae , moxifloxacin, and two strains of P. aeruginosa were used. Antibacterial effect and emergence of resistance were measured for both species over a 72-h period using an initial inoculum of about 10 8 CFU/ml. At equivalent area under the curve (AUC)/MIC ratios, S. pneumoniae was cleared from the model while P. aeruginosa was not. For S. pneumoniae , the area under the bacterial kill curve up to 72 h could be related to AUC/MIC ratio using an inhibitory maximum effect ( E max ) model (concentration required for 50% E max [EC 50 ], 45 ± 22; r 2 , 0.97). For P. aeruginosa even at the highest AUC/MIC ratio (427), bacterial clearance was insufficient for the EC 50 to be calculated. Emergence of resistance occurred with P. aeruginosa but not to any significant extent with S. pneumoniae . Emergence of resistance in P. aeruginosa as measured by population analysis profile (PAP-AUC) was dependent on drug exposure and time of exposure. In weighted least-squares regression analysis AUC/MIC ratio was predictive of PAP-AUC. When emergence of resistance was measured by the time for the colony counts on media containing antibiotic to increase by 2 logs, again AUC/MIC was the best predictor of emergence of resistance. However, for both experiments using S. pneumoniae and P. aeruginosa the correlation between all the pharmacodynamic parameters was high. These data indicate that for a given fluoroquinolone the magnitude of the AUC/MIC ratio for antibacterial effect is dependent on the bacterial species. Emergence of resistance is dependent on (i) species, (ii) duration of drug exposure, and (iii) drug exposure. A single AUC/MIC ratio magnitude is not adequate to predict antibacterial effect or emergence of resistance for all bacterial species.Keywords
This publication has 18 references indexed in Scilit:
- Pharmacodynamics of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model of InfectionAntimicrobial Agents and Chemotherapy, 2001
- The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance.Journal of Antimicrobial Chemotherapy, 2001
- Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniaeJournal of Antimicrobial Chemotherapy, 2001
- Activities of Newer Fluoroquinolones against Ciprofloxacin-Resistant Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2001
- In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniaeJournal of Antimicrobial Chemotherapy, 2001
- Streptococcus pneumoniae Response to Repeated Moxifloxacin or Levofloxacin Exposure in a Rabbit Tissue Cage ModelAntimicrobial Agents and Chemotherapy, 2001
- Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.Journal of Antimicrobial Chemotherapy, 2000
- Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterialExpert Opinion on Investigational Drugs, 1999
- Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infectionAntimicrobial Agents and Chemotherapy, 1993
- Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistanceAntimicrobial Agents and Chemotherapy, 1987